Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Epstein-barr virus and multiple sclerosis risk in the finnish maternity cohort.

Munger KL, Hongell K, Cortese M, Åivo J, Soilu-Hänninen M, Surcel HM, Ascherio A.

Ann Neurol. 2019 Sep;86(3):436-442. doi: 10.1002/ana.25532. Epub 2019 Jul 3.

PMID:
31226219
2.

Author response: 25-Hydroxyvitamin D deficiency and risk of MS among women in the Finnish Maternity Cohort.

Munger KL, Ascherio A, Soilu-Hänninen M, Surcel HM, Åivo J.

Neurology. 2018 Apr 3;90(14):668-669. doi: 10.1212/WNL.0000000000005245. No abstract available.

PMID:
29610235
3.

25-Hydroxyvitamin D deficiency and risk of MS among women in the Finnish Maternity Cohort.

Munger KL, Hongell K, Åivo J, Soilu-Hänninen M, Surcel HM, Ascherio A.

Neurology. 2017 Oct 10;89(15):1578-1583. doi: 10.1212/WNL.0000000000004489. Epub 2017 Sep 13.

4.

Risk of osteoporotic fractures in multiple sclerosis patients in southwest Finland.

Åivo J, Kurki S, Sumelahti ML, Hänninen K, Ruutiainen J, Soilu-Hänninen M.

Acta Neurol Scand. 2017 May;135(5):516-521. doi: 10.1111/ane.12623. Epub 2016 Jun 22.

PMID:
27334254
5.

Vitamin D Status During Pregnancy and Risk of Multiple Sclerosis in Offspring of Women in the Finnish Maternity Cohort.

Munger KL, Åivo J, Hongell K, Soilu-Hänninen M, Surcel HM, Ascherio A.

JAMA Neurol. 2016 May 1;73(5):515-9. doi: 10.1001/jamaneurol.2015.4800.

6.

Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta.

Åivo J, Hänninen A, Ilonen J, Soilu-Hänninen M.

J Neuroimmunol. 2015 Mar 15;280:12-5. doi: 10.1016/j.jneuroim.2015.01.005. Epub 2015 Jan 21.

PMID:
25773149
7.

A Randomised, Double-Blind, Placebo-Controlled Trial with Vitamin D3 in MS: Subgroup Analysis of Patients with Baseline Disease Activity Despite Interferon Treatment.

Aivo J, Lindsröm BM, Soilu-Hänninen M.

Mult Scler Int. 2012;2012:802796. doi: 10.1155/2012/802796. Epub 2012 Aug 5.

8.

A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis.

Soilu-Hänninen M, Aivo J, Lindström BM, Elovaara I, Sumelahti ML, Färkkilä M, Tienari P, Atula S, Sarasoja T, Herrala L, Keskinarkaus I, Kruger J, Kallio T, Rocca MA, Filippi M.

J Neurol Neurosurg Psychiatry. 2012 May;83(5):565-71. doi: 10.1136/jnnp-2011-301876. Epub 2012 Feb 22.

PMID:
22362918

Supplemental Content

Support Center